NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences $(ATAI)$ and Beckley Psytech Limited have announced a definitive agreement to merge in an all-share transaction. The deal, subject to pre-agreed BPL-003 Phase 2b success criteria, will see Beckley shareholders receive approximately 105 million new shares, valuing Beckley at around $390 million. This merger will result in Beckley owning about 31% of the combined company. atai's Supervisory and Management Boards, along with Beckley's Board of Directors, have approved the transaction, which is anticipated to close in the latter half of 2025, pending shareholder approval and customary conditions. Concurrently, atai has secured a $30 million private placement with Ferring Ventures S.A. and Adage Capital Partners LP, expected to close on June 3, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.